Allergens
BGSU Dining and Accessibility Services work hard to accommodate students with allergies, but students have differing opinions on the options available. While some praise the university's allergen-friendly dining station, Thrive, others find the options too limited or inconsistent. University staff emphasize the support systems and allergen-safe programs in
Allergens
A landmark study has found that food allergies in children under 3 decreased sharply in the years after new guidelines encouraged parents to introduce infants to common allergens, such as peanuts and eggs. The study, published in the journal Pediatrics, analyzed data from 125,000 children across nearly 50 pediatric
Allergy
A recent study published in Academia Medicine has shed light on the patterns of aeroallergen sensitivity among patients with nasobronchial allergies in Garhwal, North India. The research, conducted by Apoorva Kumar Pandey and colleagues from Sri Guru Ram Rai Institute of Medical and Health Sciences, aimed to identify the common
Allergens
A landmark study 10 years ago suggested that feeding peanut products to young babies could reduce life-threatening allergies, and new research now shows that this practice has made a significant difference in the real world. After the guidance was first issued in 2015, the rate of peanut allergies in children
Allergens
According to a recent study published in Pediatrics, introducing peanuts in infancy has led to a significant reduction in childhood peanut allergies. The study found that among children ages 0-3 years, there was a 27.2% reduction in peanut allergy after guidance for high-risk children was first issued in 2015,
Allergens
Researchers have made significant progress in developing a novel treatment for peanut allergy, using epicutaneous immunotherapy (EPIT). This approach promotes tolerance to food allergens by harnessing the power of the cutaneous immune system. The University of North Carolina's research team, led by A. Wesley Burks, has been working
Allergens
IgGenix has made significant strides in the fight against peanut allergy by announcing the initiation of its ACCELERATE Peanut Phase 1 clinical trial. The trial aims to evaluate the safety, tolerability, and potential proof of mechanism of IGNX001, a novel therapeutic candidate developed using IgGenix's proprietary SEQ SIFTER
Allergens
A recent study published in the journal Allergy has found that remission is a preferred outcome over desensitization in food allergy immunotherapy. The Phase 2b study, conducted by Prota Therapeutics Pty Ltd, directly compared the long-term benefits and risks associated with remission and desensitization in children who received high-dose peanut
Allergens
Australian clinical-stage biotechnology company, Prota Therapeutics, has announced the publication of a study in the journal Allergy, which compares remission and desensitization endpoints following food allergen oral immunotherapy (OIT). The Phase 2b follow-on study, PPOIT-003LT, reports 2-year post-treatment outcomes for Prota's remission-inducing high-dose peanut oral immunotherapies, PRT120 and
Allergens
Australian authorities have taken a significant step towards combatting life-threatening peanut allergies in infants by launching a world-first oral immunotherapy (OIT) program. The ADAPT OIT program, run by the National Allergy Centre of Excellence (NACE), aims to desensitize babies under 12 months to peanuts by administering daily doses of peanut
Allergens
Research at McMaster University in Canada has shown that early introduction of peanuts in infants may reduce the risk of peanut-induced anaphylaxis in young children. The study analyzed data from pediatric anaphylaxis presentations at Montreal's Children's Hospital between 2011 and 2019, finding a significant decrease in
